|
A more recent version of this article appeared on July 1, 2007
Papers In Press, published online ahead of print April 20, 2007
J. Lipid Res., doi:10.1194/jlr.M700071-JLR200
Submitted on February 8, 2007
Revised on March 21, 2007
Accepted on April 20, 2007
Secreted proprotein convertase subtilisin/kexin-type 9 downregulates low-density lipoprotein receptor through receptor-mediated endocytosis
Yue-Wei Qian, Robert J. Schmidt, Youyan Zhang, Shaoyou Chu, Aimin Lin, He Wang, Xiliang Wang, Thomas P. Beyer, William R. Bensch, Weiming Li, Mariam E. Ehsani, Deshun Lu, Robert J. Konrad, Patrick I. Eacho, David E. Moller, Sotirios K. Karathanasis, and Guoqing Cao
Cardiovascular Research, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN 46285
Corresponding Author: guoqing_cao{at}lilly.com
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low-density lipoprotein receptor (LDLR) protein levels. The mechanisms of this action, however, remain to be defined. We show here that recombinant human PCSK9 expressed in human embryonic kidney 293 (HEK 293) cells was readily secreted into the medium with the prosegment associated with the c-terminal domain. Secreted PCSK9 mediated cell surface LDLR degradation in a concentration and time dependent manner when added to HEK293 cells. Accordingly, cellular LDL uptake was significantly reduced as well. When infused directly into C57B6 mice, purified human PCSK9 substantially reduced hepatic LDLR protein levels and resulted in elevated plasma LDL cholesterol. When added to culture medium, fluorescently labeled PCSK9 was endocytosed and displayed endosomal-lysosomal intracellular localization in HepG2 cells, as was demonstrated by the co-localization with DiI-LDL. PCSK9 endocytosis was mediated by LDLR as either LDLR deficiency (hepatocytes from LDLR null mice) or RNAi-mediated knockdown of LDLR markedly reduced PCSK9 endocytosis. In addition, RNAi knockdown of the autosomal recessive hypercholesterolemia gene (ARH) product also significantly reduced PCSK9 endocytosis. Biochemical analysis revealed that the LDLR extracellular domain directly interacted with secreted PCSK9; thus overexpression of LDLR extracellular domain was able to attenuate the reduction of cell surface LDLR levels by secreted PCSK9. Taken together, these results reveal that secreted PCSK9 retains biological activity, is able to bind directly to the LDLR extracellular domain, and undergoes LDLR-ARH mediated endocytosis leading to accelerated intracellular degradation of the LDLR.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. S. Troutt, W. E. Alborn, G. Cao, and R. J. Konrad
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
J. Lipid Res.,
February 1, 2010;
51(2):
345 - 351.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Poirier, G. Mayer, V. Poupon, P. S. McPherson, R. Desjardins, K. Ly, M.-C. Asselin, R. Day, F. J. Duclos, M. Witmer, et al.
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation: EVIDENCE FOR AN INTRACELLULAR ROUTE
J. Biol. Chem.,
October 16, 2009;
284(42):
28856 - 28864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Li, B. Dong, S. W. Park, H.-S. Lee, W. Chen, and J. Liu
Hepatocyte Nuclear Factor 1{alpha} Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
J. Biol. Chem.,
October 16, 2009;
284(42):
28885 - 28895.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Luo, L. Warren, D. Xia, H. Jensen, T. Sand, S. Petras, W. Qin, K. S. Miller, and J. Hawkins
Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
J. Lipid Res.,
August 1, 2009;
50(8):
1581 - 1588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Y. Chan, D. E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, et al.
From the Cover: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
PNAS,
June 16, 2009;
106(24):
9820 - 9825.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. McNutt, H. J. Kwon, C. Chen, J. R. Chen, J. D. Horton, and T. A. Lagace
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
J. Biol. Chem.,
April 17, 2009;
284(16):
10561 - 10570.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Horton, J. C. Cohen, and H. H. Hobbs
PCSK9: a convertase that coordinates LDL catabolism
J. Lipid Res.,
April 1, 2009;
50(Supplement):
S172 - S177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Persson, C. Galman, B. Angelin, and M. Rudling
Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors
Endocrinology,
March 1, 2009;
150(3):
1140 - 1146.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Pandit, D. Wisniewski, J. C. Santoro, S. Ha, V. Ramakrishnan, R. M. Cubbon, R. T. Cummings, S. D. Wright, C. P. Sparrow, A. Sitlani, et al.
Functional analysis of sites within PCSK9 responsible for hypercholesterolemia
J. Lipid Res.,
June 1, 2008;
49(6):
1333 - 1343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Lambert, N. Ancellin, F. Charlton, D. Comas, J. Pilot, A. Keech, S. Patel, D. R. Sullivan, J. S. Cohn, K.-A. Rye, et al.
Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
Clin. Chem.,
June 1, 2008;
54(6):
1038 - 1045.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kourimate, C. Le May, C. Langhi, A. L. Jarnoux, K. Ouguerram, Y. Zair, P. Nguyen, M. Krempf, B. Cariou, and P. Costet
Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9
J. Biol. Chem.,
April 11, 2008;
283(15):
9666 - 9673.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. E Liyanage, A. J Hooper, J. C Defesche, J. R Burnett, and F. M van Bockxmeer
High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations
Ann Clin Biochem,
March 1, 2008;
45(2):
170 - 176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. E. Careskey, R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao, and R. J. Konrad
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
J. Lipid Res.,
February 1, 2008;
49(2):
394 - 398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. E. Alborn, G. Cao, H. E. Careskey, Y.-W. Qian, D. R. Subramaniam, J. Davies, E. M. Conner, and R. J. Konrad
Serum Proprotein Convertase Subtilisin Kexin Type 9 Is Correlated Directly with Serum LDL Cholesterol
Clin. Chem.,
October 1, 2007;
53(10):
1814 - 1819.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|